Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec and Debiopharm Group™ to Collaborate

Published: Wednesday, April 02, 2014
Last Updated: Wednesday, April 02, 2014
Bookmark and Share
Innovative partnership based on Evotec’s Target X projects.

Evotec AG has announced a research collaboration and licensing deal with Debiopharm Group™, Lausanne, Switzerland.

The objective of this collaboration is to identify and develop novel compounds having the potential to treat multiple forms of solid tumors and leukemias with defined genetic alterations.

Discovery and pre-clinical development efforts will be driven by Evotec, whilst Debiopharm will manage clinical development. Evotec will receive R&D funding and high double-digit total payments triggered by clinical, regulatory and commercial milestones, plus royalties on sales of resulting commercial products.

This program is based on Evotec’s drug discovery efforts to investigate genetically altered targets whose 'driver' role in several cancer types has been validated and on the shared objective of identifying novel therapeutic agents in a variety of cancers, including AML (Acute Myeloid Leukemia), prostate cancer and glioblastoma.

Evotec is in the unique position of being able to apply a broad range of highly sophisticated drug discovery tools including mass spectrometry and structure-based drug design for rapid and efficient development of highly promising lead series.

Debiopharm is experienced in taking to maturity promising early stage biological or small molecule drug candidates from preclinical to clinical development phase I, II and III, including subsequent out-licensing to pharmaceutical partners for sales and marketing.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are very excited about this innovative collaboration structure between Debiopharm and Evotec. It combines our proven discovery platform with Debiopharm’s ability to advance projects through clinical development in a highly efficient manner while sharing risks and rewards of Evotec’s TargetX project. There is compelling science around the target and we are confident that we will be able to position highly competitive compounds in this field that hold great potential for difficult to treat cancers.”

"This is a fine example of how drug discovery and development will be in the future: a mixture of complementarities looking to bring to a defined population of patients a drug that will change the outcome of disease" added Andrés McAllister, Chief Scientific Officer, Debiopharm International SA.

“Through this collaboration with Evotec, Debiopharm is strengthening its position in early projects with a leader in the drug discovery field” said Thierry Mauvernay, Delegate of the Board of Debiopharm Group”. Furthermore, this R&D program targeting cancers with known genetic alterations is a whole part of our strategy for personalized medicines”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec Awarded Contract to Manage NCI CBC Screening Libraries Center
Company will provide compound management services for a period of five years.
Friday, October 09, 2015
Evotec, Apeiron Biologics and Sanofi Collaborate
Evotec AG and Apeiron Biologics AG, a biotech company with a focus on immunological approaches to treat cancer, have announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies.
Monday, August 10, 2015
Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim
The milestone relates to the transition of an oncology molecule into pre-clinical development.
Tuesday, December 10, 2013
Evotec AG Reports H1 2013 Results
Company predicts top-line growth in the second half of the year 2013 due to expected milestones.
Friday, August 09, 2013
Scientific News
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Nanosensors Could Determine Tumours’ Ability to Remodel Tissue
Researchers design nanosensors that can profile tumours, focusing on protease levels.
Developing Novel Ear Infection Treatments
Research team engineers antibiotic gel for treating middle ear infections.
Blood Pressure Drug May Boost Effectiveness of Lung Cancer Treatment
Researchers at Imperial College London have suggested that the blood pressure drug may make a type of lung cancer treatment more effective.
Wearable Microscope Can Measure Fluorescent Dyes Through Skin
UCLA research could make monitoring disease biomarkers easier and more cost-effective.
Potential of New Insect Control Traits in Agriculture
Researchers have discovered a protein that shows promise as an alternate corn rootworm control mechanism.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!